Costs (On Termination by CureVac for Cause). If CureVac elects the CureVac Cease Option following a termination of a Program by CureVac for cause in accordance with Section 14.3, 14.4 or 14.5, GSK shall reimburse CureVac for the Development Costs set forth in the respective R&D Plan until the effective date of termination and reimburse CureVac for its demonstrable stranded costs arising from the early termination of the R&D Plan. CureVac shall use reasonable endeavors to mitigate those stranded costs.
Appears in 3 contracts
Samples: Collaboration and License Agreement (CureVac N.V.), Collaboration and License Agreement (CureVac N.V.), Collaboration and License Agreement (CureVac B.V.)
Costs (On Termination by CureVac for Cause). If CureVac elects the CureVac Cease Option following a termination of a Program by CureVac for cause in accordance with Section 14.314.4, 14.4 14.5 or 14.514.6, GSK shall reimburse CureVac for the Development Costs set forth in the respective R&D Plan until the effective date of termination and reimburse CureVac for its demonstrable stranded costs arising from the early termination of the COVID R&D PlanPlan(s). CureVac shall use reasonable endeavors to mitigate those stranded costs.
Appears in 2 contracts
Samples: Covid Collaboration and License Agreement, Covid Collaboration and License Agreement (CureVac N.V.)
Costs (On Termination by CureVac for Cause). If CureVac elects the CureVac Cease Option following a termination of a Program by CureVac for cause in accordance with Section 14.314.4, 14.4 14.5 or 14.514.6, GSK shall reimburse CureVac for the Development Costs set forth in the respective R&D Plan until the effective date of termination and reimburse CureVac for its demonstrable stranded costs arising from the early termination of the COVID R&D PlanPlan(s). CureVac shall use reasonable endeavors to mitigate those stranded costs.. β
Appears in 1 contract
Costs (On Termination by CureVac for Cause). If CureVac elects the CureVac Cease Option following a termination of a Program by CureVac for cause in accordance with Section 14.314.4, 14.4 14.5 or 14.514.6, GSK shall reimburse CureVac for the Development Costs set forth in the respective R&D Plan until the effective date of termination and reimburse CureVac for its demonstrable β stranded costs arising from the early termination of the COVID R&D PlanPlan(s). CureVac shall use reasonable endeavors to mitigate those stranded costs.
Appears in 1 contract
Samples: Covid Collaboration and License Agreement (CureVac N.V.)
